https://www.pharmaceutical-technology.com/data-insights/defactinib-hydrochloride-verastem-ovarian-cancer-likelihood-of-approval/
Defactinib hydrochloride is under clinical development by Verastem and currently in Pre-Registration for Ovarian Cancer.
ovarian cancerdefactinibhydrochloridelikelihoodapproval
https://www.pharmaceutical-technology.com/data-insights/defactinib-hydrochloride-verastem-metastatic-melanoma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-312656&utm_campaign=recommended-articles-pi
Defactinib hydrochloride is under clinical development by Verastem and currently in Phase II for Metastatic Melanoma.
metastatic melanomadefactinibhydrochloridelikelihoodapproval